{"id":650380,"date":"2023-05-04T18:04:01","date_gmt":"2023-05-04T18:04:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=650380"},"modified":"2023-05-04T18:04:01","modified_gmt":"2023-05-04T18:04:01","slug":"trastuzumab-biosimilar-landscape-report-2023-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/trastuzumab-biosimilar-landscape-report-2023-by-delveinsight_650380.html","title":{"rendered":"Trastuzumab Biosimilar Landscape Report 2023 by DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1683185052.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Trastuzumab Biosimilar Landscape Report 2023 by DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1683185052.png\" alt=\"Trastuzumab Biosimilar Landscape Report 2023 by DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Trastuzumab Biosimilar Landscape Report 2023 by DelveInsight<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s, \u201cTrastuzumab Biosimilar Insight, 2023\u201d report provides comprehensive insights about 35+ companies and 35+ marketed and pipeline drugs in Trastuzumab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/div>\n<p style=\"text-align: justify;\"><strong>DelveInsight launched a new report on <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/trastuzumab-biosimilars-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Trastuzumab Biosimilar Insights 2023<\/a>.<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s, &ldquo;Trastuzumab Biosimilar Insight, 2023&rdquo; report provides comprehensive insights about 35+ companies and 35+ marketed and pipeline drugs in Trastuzumab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.&nbsp;<\/p>\n<p style=\"text-align: justify;\">Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer. It is specifically used for cancer that is HER2 receptor positive. It may be used by itself or together with other chemotherapy medication. Trastuzumab is a humanized IgG1 kappa monoclonal antibody that selectively binds with high affinity to the extracellular domain of the human epidermal growth factor receptor 2 protein, HER2. Trastuzumab is produced by recombinant DNA technology in a mammalian cell (Chinese Hamster Ovary) culture which may contain the antibiotic gentamicin. Gentamicin is not detectable in the final product. Herceptin (trastuzumab) for injection is a sterile, white to pale yellow, preservative-free lyophilized powder with a cake-like appearance, for intravenous administration.<\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/trastuzumab-biosimilars-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Click here and get access to free sample pages of the report<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/trastuzumab-biosimilars-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Trastuzumab Biosimilars Marketed Drugs<\/a><\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Kanjinti: Amgen<\/li>\n<li>Herzuma: Celltrion<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Trastuzumab Emerging drugs:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>EG12014: EirGenix<\/li>\n<li>HD201: Prestige BioPharma<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Request for a detailed sample copy of the report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/trastuzumab-biosimilars-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">https:\/\/www.delveinsight.com\/sample-request\/trastuzumab-biosimilars-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of contents:<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Key Insights<\/p>\n<p style=\"text-align: justify;\">2. Trastuzumab Biosimilars: Snapshot<\/p>\n<p style=\"text-align: justify;\">3. Executive Summary<\/p>\n<p style=\"text-align: justify;\">4. Regulatory Outlook For Biosimilars<\/p>\n<p style=\"text-align: justify;\">5. Trastuzumab (Reference Product: Herceptin)<\/p>\n<p style=\"text-align: justify;\">6. Research and Development<\/p>\n<p style=\"text-align: justify;\">7. Herceptin Biosimilar: Emerging Opportunities<\/p>\n<p style=\"text-align: justify;\">8. Trastuzumab: Biosimilars Assessment<\/p>\n<p style=\"text-align: justify;\">9. Trastuzumab Biosimilars Profiles: By Company<\/p>\n<p style=\"text-align: justify;\">10. Trastuzumab Biosimilars: Comparative Landscape: By Company<\/p>\n<p style=\"text-align: justify;\">11. Trastuzumab Biosimilars: Competitive Landscape<\/p>\n<p style=\"text-align: justify;\">12. Market Drivers<\/p>\n<p style=\"text-align: justify;\">13. Market Barriers<\/p>\n<p style=\"text-align: justify;\">14. SWOT Analysis<\/p>\n<p style=\"text-align: justify;\">15. Appendix&nbsp;<\/p>\n<p style=\"text-align: justify;\">16. Bibliography<\/p>\n<p style=\"text-align: justify;\">17. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">18. Disclaimer<\/p>\n<p style=\"text-align: justify;\">19. About DelveInsight<\/p>\n<p style=\"text-align: justify;\"><strong>Download our full report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/trastuzumab-biosimilars-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">https:\/\/www.delveinsight.com\/report-store\/trastuzumab-biosimilars-insight<\/a><\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=trastuzumab-biosimilar-landscape-report-2023-by-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=trastuzumab-biosimilar-landscape-report-2023-by-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Trastuzumab Biosimilar Landscape Report 2023 by DelveInsight DelveInsight\u2019s, \u201cTrastuzumab Biosimilar Insight, 2023\u201d report provides comprehensive insights about 35+ companies and 35+ marketed and pipeline drugs in Trastuzumab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/trastuzumab-biosimilar-landscape-report-2023-by-delveinsight_650380.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-650380","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/650380","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=650380"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/650380\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=650380"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=650380"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=650380"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}